Cassidy Seeks Specifics On FDA Study Of Mifepristone REMS

By Cara Smith / October 17, 2025 at 4:05 PM

Sen. Bill Cassidy (R-LA) in a Thursday (Oct. 16) letter is encouraging FDA to study safety concerns resulting from the removal of in-person dispensing requirements of mifepristone, that, if reinstated, would eliminate telehealth access to abortion pills.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.